These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32385540)

  • 41. Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial.
    Kuramitsu S; Kazuno Y; Sonoda S; Domei T; Jinnouchi H; Yamaji K; Soga Y; Shirai S; Ando K; Saito S
    Eur Heart J Cardiovasc Imaging; 2016 Jan; 17(1):34-40. PubMed ID: 26333375
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incidence of late-acquired stent malapposition of drug eluting stents with second generation permanent and biodegradable polymer coatings-A prospective, randomized comparison using optical coherence tomography.
    Roth C; Gangl C; Dalos D; Delle-Karth G; Neunteufl T; Berger R
    J Interv Cardiol; 2018 Dec; 31(6):780-791. PubMed ID: 30479028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans: the TIMELESS study.
    Vesga B; Hernandez H; Moncada M; Gasior P; Higuera S; Dager A; Arana C; Delgado JA; Généreux P; Maehara A; Granada JF
    Coron Artery Dis; 2017 Mar; 28(2):126-134. PubMed ID: 27879518
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optical Coherence Tomography Tissue Coverage and Characterization with Grey-Scale Signal Intensity Analysis After Bifurcation Stenting with a New Generation Bioabsorbable Polymer Drug-Eluting Stent.
    Rai H; Hussein H; Colleran R; Xhepa E; Wiebe J; Pinieck S; Cassese S; Joner M; Kastrati A; Byrne RA; Foley DP
    Cardiovasc Revasc Med; 2020 Mar; 21(3):277-285. PubMed ID: 31155492
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
    Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of long-term follow-up with neointimal coverage and stent apposition after sirolimus-eluting stent implantation by optical coherence tomography.
    Li S; Gai L; Yang T; Zhang L; Xu X; Bai Q; Xu H; Wang Y
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):768-75. PubMed ID: 22639418
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of serial optical coherence tomography imaging following aggressive stent expansion technique: insight from the MECHANISM study.
    Sasaki W; Ishida M; Itoh T; Uchimura Y; Oda H; Taguchi Y; Kaneko K; Sakamoto T; Goto I; Sakuma M; Terashita D; Otake H; Shinke T; Morino Y
    Int J Cardiovasc Imaging; 2021 Feb; 37(2):419-428. PubMed ID: 33034867
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serial OCT Imaging in Vascular Healing After Everolimus-Eluting Stent Implantation.
    Yano H; Horinaka S; Ishimitsu T
    JACC Cardiovasc Imaging; 2018 Jan; 11(1):147-148. PubMed ID: 28528155
    [No Abstract]   [Full Text] [Related]  

  • 49. Comparison of neointimal coverage and extra-stent lumen between sirolimus and everolimus-eluting stent using optical coherence tomography.
    Oda T; Okamura T; Yamada J; Miyagi N; Uehara H; Nao T; Tateishi H; Maeda T; Nakamura T; Shiraishi K; Nakashima T; Nishimura S; Miura T; Matsuzaki M; Yano M
    Heart Vessels; 2016 Apr; 31(4):449-56. PubMed ID: 25614415
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of neointimal coverage between everolimus-eluting stents and sirolimus-eluting stents: an optical coherence tomography substudy of the RESET (Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial).
    Kubo T; Akasaka T; Kozuma K; Kimura K; Kawamura M; Sumiyoshi T; Ino Y; Morino Y; Tanabe K; Kadota K; Kimura T;
    EuroIntervention; 2015 Sep; 11(5):564-71. PubMed ID: 26390517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Difference in vascular response between sirolimus-eluting- and everolimus-eluting stents in ostial left circumflex artery after unprotected left main as observed by optical coherence tomography.
    Fujino Y; Attizzani GF; Tahara S; Naganuma T; Takagi K; Yabushita H; Wang W; Tanaka K; Matsumoto T; Kawamoto H; Yamada Y; Amano S; Watanabe Y; Warisawa T; Sato T; Mitomo S; Kurita N; Ishiguro H; Hozawa K; Tsukahara T; Motosuke M; Bezerra HG; Nakamura S; Nakamura S
    Int J Cardiol; 2017 Mar; 230():284-292. PubMed ID: 28065691
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Temporal changes of incomplete stent apposition during early phase after everolimus-eluting stent implantation: serial optical coherence tomography analyses at 2-week and 4-month.
    Wakabayashi H; Ando H; Nakano Y; Takashima H; Waseda K; Shimoda M; Ohashi H; Suzuki A; Sakurai S; Amano T
    Int J Cardiovasc Imaging; 2021 Feb; 37(2):411-417. PubMed ID: 32926310
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of lesion angle on optical coherence tomography findings and clinical outcomes after drug-eluting stent implantation in curved vessels.
    Nakamura S; Kimura S; Nakagama S; Misawa T; Mizusawa M; Hayasaka K; Yamakami Y; Kojima K; Sagawa Y; Hishikari K; Hikita H; Takahashi A; Hirao K
    Int J Cardiovasc Imaging; 2019 Dec; 35(12):2147-2155. PubMed ID: 31359232
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.
    Poerner TC; Otto S; Gassdorf J; Nitsche K; Janiak F; Scheller B; Goebel B; Jung C; Figulla HR
    Circ Cardiovasc Interv; 2014 Dec; 7(6):760-7. PubMed ID: 25371536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Five-Year Optical Coherence Tomography in Patients With ST-Segment-Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents.
    Gomez-Lara J; Brugaletta S; Jacobi F; Ortega-Paz L; Ñato M; Roura G; Romaguera R; Ferreiro JL; Teruel L; Gracida M; Martin-Yuste V; Freixa X; Masotti M; Gomez-Hospital JA; Sabate M; Cequier A
    Circ Cardiovasc Interv; 2016 Oct; 9(10):. PubMed ID: 27702766
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of vascular response between everolimus-eluting stent and bare metal stent implantation in ST-segment elevation myocardial infarction assessed by optical coherence tomography.
    Ino Y; Kubo T; Tanaka A; Liu Y; Tanimoto T; Kitabata H; Shiono Y; Shimamura K; Orii M; Komukai K; Satogami K; Matsuo Y; Yamano T; Yamaguchi T; Hirata K; Imanishi T; Akasaka T
    Eur Heart J Cardiovasc Imaging; 2015 May; 16(5):513-20. PubMed ID: 25428946
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents: Insights of the TROFI II Trial.
    Gomez-Lara J; Brugaletta S; Ortega-Paz L; Vandeloo B; Moscarella E; Salas M; Romaguera R; Roura G; Ferreiro JL; Teruel L; Gracida M; Windecker S; Serruys PW; Gomez-Hospital JA; Sabaté M; Cequier A
    JACC Cardiovasc Interv; 2018 Aug; 11(16):1559-1571. PubMed ID: 29805111
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial.
    Kim JS; Jang IK; Fan C; Kim TH; Kim JS; Park SM; Choi EY; Lee SH; Ko YG; Choi D; Hong MK; Jang Y
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1240-7. PubMed ID: 20129551
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice.
    Zanchin C; Ueki Y; Zanchin T; Häner J; Otsuka T; Stortecky S; Koskinas KC; Siontis GCM; Praz F; Moschovitis A; Hunziker L; Valgimigli M; Pilgrim T; Heg D; Windecker S; Räber L
    JACC Cardiovasc Interv; 2019 Sep; 12(17):1665-1675. PubMed ID: 31422088
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Very late stent thrombosis in everolimus-eluting stent with predisposing mechanical factors: Differential features.
    Jaguszewski MJ; Cortes C; Daucher H; Schincariol M; Halejcio M; Besuch P; Gutiérrez-Chico JL
    Cardiol J; 2017; 24(4):345-349. PubMed ID: 28831778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.